Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system ...

A research team at the Medical University of Vienna has uncovered a complex role for histone deacetylases (HDACs) in the ...

The report includes clinical and nonclinical drug profiles, therapeutic assessments, and details on emerging drugs like Ricolinostat and CKD 506. Ideal for stakeholders in oncology and therapeutic R&D ...

ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, today announced a poster presentation at The Professional Society for Health Economics and Outcomes Research (ISPOR) conference being held May ...

The FDA granted fast track status to givinostat for treating high-risk polycythemia vera, supporting its potential shown in ...

A new study has identified the HDAC11 protein, an enzyme involved in cellular regulation, as a new potential therapeutic ...

Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone deacetylase (HDAC) inhibitor, which was approved by the FDA in November 2009 to treat cutaneous T cell lymphoma (CTCL ...

Tumor immunotherapy has become a standard of care for treating various cancers, with immune checkpoint inhibitors targeting the PD-L1/PD-1 axis proving particularly effective. While PD-L1 expression ...